Hydrogen sulfide-releasing anti-inflammatory drugs for chemoprevention and treatment of cancer

Pharmacological Research

Volumn 111, Issue , 2016, Pages 652-658

  Ianaro, Angela ^a   Cirino, Giuseppe ^a,b   Wallace, John L ^b,c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSIDADE CAMILO CASTELO BRANCO   (Brazil)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Chemoprevention; Colon cancer; Hydrogen sulfide; Inflammation; Melanoma; Transcriptomics

Indexed keywords

ATB 346; HYDROGEN SULFIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT;

ABERRANT CRYPT FOCUS; CANCER CHEMOTHERAPY; CANCER PREVENTION; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; INTESTINE CANCER; INTESTINE POLYP; MELANOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR PROMOTION; ANIMAL; CHEMOPROPHYLAXIS; INTESTINE TUMOR;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICARCINOGENIC AGENTS; CHEMOPREVENTION; HUMANS; HYDROGEN SULFIDE; INTESTINAL NEOPLASMS; MELANOMA;

EID: 84979742634     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.07.041     Document Type: Review

References (80)

1. [1] Wallace, J.L., Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself?. Physiol. Rev. 88 (2008), 1547–1565.
2. [2] Smalley, W., Ray, W.A., Daugherty, J., Griffin, M.R., Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch. Intern. Med. 159 (1999), 161–166.
3. [3] Chan, T.A., Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol. 3 (2002), 166–174.
4. [4] Ulrich, C.M., Bigler, J., Potter, J.D., Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat. Rev. Cancer 6 (2006), 130–140.
5. [5] Din, F.V., Theodoratou, E., Farrington, S.M., Tenesa, A., Barnetson, R.A., Cetnarskyj, R., Stark, L., Porteous, M.E., Campbell, H., Dunlop, M.G., Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 59 (2010), 1670–1679.
6. [6] Wallace, J.L., Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. World J. Gastroenterol. 19 (2013), 1861–1876.
7. [7] Wang, R., Guo, L., Wang, P., Yang, W., Lu, Y., Huang, Z., Tang, C., Chemoprevention of cancers in gastrointestinal tract with cyclooxygenase 2 inhibitors. Curr. Pharm. Des. 19 (2014), 115–125.
8. [8] Bertagnolli, M.M., Eagle, C.J., Zauber, A.G., Redston, M., Solomon, S.D., Kim, K., Tang, J., Rosenstein, R.B., Wittes, J., Corle, D., Hess, T.M., Woloj, G.M., Boisserie, F., Anderson, W.F., Viner, J.L., Bagheri, D., Burn, J., Chung, D.C., Dewar, T., Foley, T.R., Hoffman, N., Macrae, F., Pruitt, R.E., Saltzman, J.R., Salzberg, B., Sylwestrowicz, T., Gordon, G.B., Hawk, E.T., Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 355 (2006), 873–884.
9. [9] Arber, N., Eagle, C.J., Spicak, J., Rácz, I., Dite, P., Hajer, J., Zavoral, M., Lechuga, M.J., Gerletti, P., Tang, J., Rosenstein, R.B., Macdonald, K., Bhadra, P., Fowler, R., Wittes, J., Zauber, A.G., Solomon, S.D., Levin, B., Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 355 (2006), 885–895.
10. [10] Wallace, J.L., Devchand, P.R., Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense. Br. J. Pharmacol. 145 (2005), 275–282.
11. [11] Solomon, S.D., McMurray, J.J., Pfeffer, M.A., Wittes, J., Fowler, R., Finn, P., Anderson, W.F., Zauber, A., Hawk, E., Bertagnolli, M., Cardiovascular risk with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 352 (2005), 1071–1080.
12. [12] Winkelmayer, W.C., Waikar, S.S., Mogun, H., Solomon, D.H., Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury. Am. J. Med. 121 (2008), 1092–1098.
13. [13] Wallace, J.L., Wang, R., Hydrogen sufide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter. Nat. Rev. Drug Discov. 14 (2015), 329–345, 10.1038/nrd4433.
14. [14] Wallace, J.L., Ferraz, J.G., Muscara, M.N., Hydrogen sulfide: an endogenous mediator of resolution of inflammation and injury. Antioxid. Redox Signal. 17 (2012), 58–67.
15. [15] Kimura, K., Shibuya, N., Kimura, Y., Hydrogen sulfide is a signaling molecule and a cytoprotectant. Antioxid. Redox Signal. 17 (2012), 45–57.
16. [16] Wallace, J.L., Dicay, M., McKnight, W., Martin, G.R., Hydrogen sulfide enhances ulcer healing in rats. FASEB J. 21 (2007), 4070–4076.
17. [17] Wallace, J.L., Vong, L., McKnight, W., Dicay, M., Martin, G.R., Endogenous and exogenous hydrogen sulfide promotes resolution of colitis in rats. Gastroenterology 137 (2009), 569–578.
18. [18] Flannigan, K.L., Ferraz, J.G., Wang, R., Wallace, J.L., Enhanced synthesis and diminished degradation of hydrogen sulfide in experimental colitis: a site-specific, pro-resolution mechanism. PLoS One, 8, 2013, e71962.
19. [19] Fiorucci, S., Antonelli, E., Distrutti, E., Rizzo, G., Mencarelli, A., Orlandi, S., Zanardo, R., Renga, B., Di Sante, M., Morelli, A., Cirino, G., Wallace, J.L., Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. Gastroenterology 129 (2005), 1210–1224.
20. [20] Mard, S.A., Neisi, N., Solgi, G., Hassanpour, M., Darbor, M., Maleki, M., Gastroprotective effect of NaHS against mucosal lesions induced by ischemia-reperfusion injury in rat. Dig. Dis. Sci. 57 (2012), 1496–1503, 10.1007/s10620-012-2051-5.
21. [21] Zayachkivska, O., Havryluk, O., Hrycevych, N., Bula, N., Grushka, O., Wallace, J.L., Cytoprotective effects of hydrogen sulfide in novel rat models of non-erosive esophagitis. PLoS One, 9, 2014, e110688, 10.1371/journal.pone.0110688.
22. [22] Magierowski, M., Jasnos, K., Kwiecien, S., Drozdowicz, D., Surmiak, M., Strzalka, M., Ptak-Belowska, A., Wallace, J.L., Brzozowski, T., Endogenous prostaglandins and afferent sensory nerves in gastroprotective effect of hydrogen sulfide against stress-induced gastric lesions. PLoS One, 10, 2015, e0118972, 10.1371/journal.pone.0118972.
23. [23] Wallace, J.L., Dicay, M., McKnight, W., Martin, G.R., Hydrogen sulfide enhances ulcer healing in rats. FASEB J. 21 (2007), 4070–4076.
24. [24] Zanardo, R.C.O., Brancaleone, V., Distrutti, E., Fiorucci, S., Cirino, G., Wallace, J.L., Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J. 20 (2006), 2118–2120.
25. [25] Wallace, J.L., Blackler, R.W., Chan, M.V., da Silva, G.J., Flannigan, K.L., Gamaniek, I., Manko, A., Wang, L., Motta, J.P., Buret, A.G., Anti-inflammatory and cytoprotective actions of hydrogen sulfide: translation to therapeutics. Antioxid. Redox Signal. 22 (2015), 398–410, 10.1089/ars.2014.5901.
26. [26] Distrutti, E., Sediari, L., Mencarelli, A., Renga, B., Orlandi, S., Antonelli, E., Roviezzo, F., Morelli, A., Cirino, G., Wallace, J.L., Fiorucci, S., Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. J. Pharmacol. Exp. Ther. 316 (2006), 325–335.
27. 2S-releasing drugs as pharmaceuticals. J. Med. Chem. 53 (2010), 6275–6286.
28. [28] Wallace, J.L., Caliendo, G., Santagada, V., Cirino, G., Fiorucci, S., Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulphide-releasing diclofenac derivative in the rat. Gastroenterology 132 (2007), 261–271.
29. [29] Wallace, J.L., Caliendo, G., Santagada, V., Cirino, G., Markedly reduced toxicity of a hydrogen sulfide-releasing derivative of naproxen (ATB-346). Br. J. Pharmacol. 159 (2010), 1236–1246.
30. [30] Whiteman, M., Haigh, R., Tarr, J.M., Gooding, K.M., Shore, A.C., Winyard, P.G., Detection of hydrogen sulfide in plasma and knee-joint synovial fluid from rheumatoid arthritis patients: relation to clinical and laboratory measures of inflammation. Ann. N. Y. Acad. Sci. 1203 (2010), 146–150, 10.1111/j.1749-6632.2010.05556.x.
31. [31] Li, L., Rossoni, G., Sparatore, A., Lee, L.C., Del Soldato, P., Moore, P.K., Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative. Free Radic. Biol. Med. 42 (2007), 706–719.
32. [32] Ward, J.M., Yamamoto, R.S., Brown, C.A., Pathology of intestinal neoplasms and other lesions in rats exposed to azoxymethane. J. Natl. Cancer Inst. 51 (1973), 1029–1039.
33. [33] Bird, R.P., Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett. 37 (1987), 147–151.
34. [34] Bak, A.W., McKnight, W., Li, P., Del Soldato, P., Calignano, A., Cirino, G., Wallace, J.L., Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. Life Sci. 62 (1998), PL367–PL373.
35. [35] Martin, J.E., Le Leu, R.K., Hu, Y., Young, G.P., R-flurbiprofen suppresses distal nonmucin-producing colorectal tumors in azoxymethane-treated rats, without suppressing eicosanoid production. Am. J. Physiol. Gastrointest. Liver Physiol. 298 (2010), G860–G864.
36. [36] Elsheikh, W., Blackler, R.W., Flannigan, K.L., Wallace, J.L., Enhanced chemopreventive effects of a hydrogen sulfide-releasing anti-inflammatory drug (ATB-346) in experimental colorectal cancer. Nitric Oxide 41 (2014), 131–137.
37. [37] Gemici, B., Elsheikh, W., Feitosa, K.B., Costa, S.K., Muscara, M.N., Wallace, J.L., H2S-releasing drugs: anti-inflammatory, cytoprotective and chemopreventive potential. Nitric Oxide 46 (2015), 25–31, 10.1016/j.niox.2014.11.010.
38. [38] Sengupta, A., Ghosh, S., Das, R.K., Bhattacharjee, S., Bhattacharya, S., Chemopreventive potential of diallylsulfide, lycopene and theaflavin during chemically induced colon carcinogenesis in rat colon through modulation of cyclooxygenase-2 and inducible nitric oxide synthase pathways. Eur. J. Cancer Prev. 15 (2006), 301–305.
39. [39] Wallace J.L., Cirino G., Santagada V., Caliendo G., Hydrogen sulfide derivatives of nonsteroidal anti-inflammatory drugs, United States Patent Application No. WO/2008/009127 (2008).
40. [40] Fiorucci, S., Orlandi, S., Mencarelli, A., Caliendo, G., Santagada, V., Distrutti, E., Santucci, L., Cirino, G., Wallace, J.L., Enhanced activity of a hydrogen sulphide releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. Br. J. Pharmacol. 150 (2007), 996–1002.
41. [41] Blackler, R.W., Motta, J.P., Manko, A., Workentine, M., Bercik, P., Surette, M.G., Wallace, J.L., Hydrogen sulphide protects against NSAID-enteropathy through modulation of bile and the microbiota. Br. J. Pharmacol. 172 (2015), 992–1004, 10.1111/bph.12961.
42. [42] Blackler, R.W., De Palma, G., Manko, A., Da Silva, G.J., Flannigan, K.L., Bercik, P., Surette, M.G., Buret, A.G., Wallace, J.L., Deciphering the pathogenesis of NSAID enteropathy using proton pump inhibitors and a hydrogen sulfide-releasing NSAID. Am. J. Physiol. Gastrointest. Liver Physiol. 308 (2015), G994–1003.
43. [43] Motta, J.P., Flannigan, K.L., Agbor, T.A., Beatty, J.K., Blackler, R.W., Workentine, M.L., Da Silva, G.J., Wang, R., Buret, A.G., Wallace, J.L., Hydrogen sulfide protects from colitis and restores intestinal microbiota biofilm and mucus production. Inflamm. Bowel Dis. 21 (2015), 1006–1017, 10.1097/MIB.0000000000000345.
44. [44] Mantovani, A., Allavena, P., Sica, A., Balkwill, F., Cancer-related inflammation. Nature 454 (2008), 436–444.
45. [45] Moser, A.R., Pitot, H.C., Dove, W.F., A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247 (1990), 322–324.
46. Min/+ mouse model of intestinal tumorigenesis. PLoS One, 11, 2016, e0147289, 10.1371/journal.pone.0147289.
47. + mice. Asian Pac. J. Cancer Prev. 13 (2012), 1115–1118.
48. [48] Narushima, Y., Unno, M., Nakagawara, K., Mori, M., Miyashita, H., Suzuki, Y., et al. Structural chromosomal localization and expression of mouse genes encoding type III Reg, RegIII alpha, RegIII beta, RegIII gamma. Gene 185 (1997), 159–168.
49. [49] Barnett, M.P.G., McNabb, W.C., Cookson, A.L., Zhu, S., Davy, M., Knoch, B., Nones, K., Hodgkinson, A.J., Roy, N.C., Changes in colon gene expression associated with increased colon inflammation in interleukin-10 gene-deficient mice inoculated with Enterococcus species. BMC Immunol., 11, 2010, 39, 10.1186/1471-2172-11-39.
50. [50] Blackler, R., Syer, S., Bolla, M., Ongini, E., Wallace, J.L., Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence. PLoS One, 7, 2012, e35196, 10.1371/journal.pone.0035196.
51. [51] Valladares-Ayerbes, M., Diaz-Prado, S., Reboredo, M., Medina, V., Iglesias-Diaz, P., Lorenzo-Patino, M.J., Campelo, R.G., Haz, M., Santamarina, I., Antón-Aparicio, L.M., Bioinformatics approach to mRNA markers discovery for detection of circulating tumor cells in patients with gastrointestinal cancer. Cancer Detect. Prev. 32 (2008), 236–250.
52. [52] Rechreche, H., Montalto, G., Mallo, G.V., Vasseur, S., Marasa, L., Soubeyran, P., Dagorn, J.C., Iovanna, J.L., Pap, reg Ialpha and reg Ibeta mRNAs are concomitantly up-regulated during human colorectal carcinogenesis. Int. J. Cancer 81 (1999), 688–694.
53. [53] Macadam, R.C., Sarela, A.I., Farmery, S.M., Robinson, P.A., Markham, A.F., Guillou, P.J., Death from early colorectal cancer is predicted by the presence of transcripts of the REG gene family. Br. J. Cancer 83 (2000), 188–195.
54. [54] Wiese, A.H., Auer, J., Lassmann, S., Nährig, J., Rosenberg, R., Höfler, H., Rüger, R., Werner, M., Identification of gene signatures for invasive colorectal tumor cells. Cancer Detect. Prev. 31 (2007), 282–295.
55. [55] Zhu, Y., Liu, X., Sköld, C.M., Wang, H., Kohyama, T., Wen, F.Q., Ertl, R.F., Rennard, S.I., Collaborative interactions between neutrophil elastase and metalloproteinases in extracellular matrix degradation in three-dimensional collagen gels. Respir. Res. 2 (2001), 300–305.
56. [56] Kodela, R., Nath, N., Chattopadhyay, M., Nesbitt, D.E., Velázquez-Martínez, C.A., Kashfi, K., Hydrogen sulfide-releasing naproxen suppresses colon cancer cell growth and inhibits NF-κB signaling. Drug Des. Dev. Ther. 9 (2015), 4873–4882.
57. [57] Chattopadhyay, M., Kodela, R., Nath, N., Dastagirzada, Y.M., Velaquez-Martinez, C.A., Boring, D., Kashfi, K., Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect. Biochem. Pharmacol. 83 (2012), 715–722, 10.1016/j.bcp.2011.12.018.
58. [58] Kashfi, K., Anti-cancer activity of new designer hydrogen sulfide-donating hybrids. Antioxid. Redox Signal. 20 (2014), 831–846, 10.1089/ars.2013.5308.
59. [59] Lee, Z., Zhou, J., Chen, C.S., Zhao, Y., Tan, C.H., Li, L., Moore, P.K., Deng, L.W., The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo. PLoS One, 6, 2011, e21077.
60. [60] De Preter, G., Deriemaeker, C., Danhier, P., Brisson, L., Cao Pham, T.T., Gregoire, V., Jordan, B.F., Sonveaux, P., Gallez, B., Fast hydrogen sulfide-releasing donor increases the tumor response to radiotherapy. Mol. Cancer Ther. 15 (2016), 154–161, 10.1158/1535-7163.
61. [61] Yang, G., Zhao, K., Ju, Y., Mani, S., Cao, Q., Puukila, S., Khaper, K., Wu, K., Wang, R., Hydrogen sulfide protects against cellular senescence via S-sulfydration of Keap1 and activation of Nrf2. Antioxid. Redox Signal. 18 (2013), 1906–1919.
62. [62] Farrugia, G., Balzan, R., The proapoptotic effect of traditional and novel nonsteroidal anti-inflammatory drugs in mammalian and yeast cells. Oxid. Med. Cell. Longevity, 2013, 504230, 10.1155/2013/504230.
63. [63] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J. Clin.(66), 2016, 7–30, 10.3322/caac.21332.
64. [64] Zelenay, S., Van Der Veen, A.G., Bottcher, J.P., Snelgrove, K.J., Rogers, N., Acton, S.E., Chakravarty, P., Girotti, M.R., Marais, R., Quezada, S.A., Sahai, E., Reis e Sousa, C., Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162 (2015), 1257–1270.
65. [65] Wallace, J.L., Polypharmacy of osteoarthritis: the perfect intestinal storm. Dig. Dis. Sci. 58 (2013), 3088–3093, 10.1007/s10620-013-2777-8.
66. [66] Kearney, P.M., Baigent, C., Godwin, J., Halls, H., Emberson, J.R., Patrono, C., Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials. BMJ 332 (2006), 1302–1308.
67. [67] E. Panza, G. Ercolano, C. Armogida, G. Sessa, G. Pirozzi, G. Cirino, J.L. Wallace, A. Ianaro, ATB-346, a novel hydrogen sulfide-releasing anti-inflammatory drug, induces apoptosis of human melanoma cells and inhibits melanoma development in vivo, Pharmacol. Res. in press.
68. [68] Berkelhammer, J., Oxenhandler, R.W., Hook, R.R. Jr., Hennessy, J.M., Development of a new melanoma model in C57BL/6 mice. Cancer Res. 42 (1982), 3157–3163.
69. [69] Dhawan, P., Richmond, A., Role of CXCL1 in tumorigenesis of melanoma. J. Leukoc. Biol. 72 (2002), 9–18.
70. [70] Maurer, G., Tarkowski, B., Baccarini, M., Raf kinases in cancer—Roles and therapeutic opportunities. Oncogene 30 (2011), 3477–3488, 10.1038/onc.2011.160.
71. [71] Panza, E., De Cicco, P., Armogida, C., Scognamiglio, G., Gigantino, V., Botti, G., Germano, D., Napolitano, M., Papapetropoulos, A., Bucci, M., Cirino, G., Ianaro, A., Pigment Cell Melanoma Res. 28 (2015), 61–72.
72. [72] Hodis, E., Watson, I.R., Kryukov, G.V., Arold, S.T., Imielinski, M., Theurillat, J.P., Nickerson, E., Auclair, D., Li, L., Place, C., Dicara, D., Ramos, A.H., Lawrence, M.S., Cibulskis, K., Sivachenko, A., Voet, D., Saksena, G., Stransky, N., Onofrio, R.C., Winckler, W., Ardlie, K., Wagle, N., Wargo, J., Chong, K., Morton, D.L., Stemke-Hale, K., Chen, G., Noble, M., Meyerson, M., Ladbury, J.E., Davies, M.A., Gershenwald, J.E., Wagner, S.N., Hoon, D.S., Schdendorf, D., Lander, E.S., Gabriel, S.B., Getz, G., Garraway, L.A., Chin, L., A landscape of driver mutations in melanoma. Cell 150 (2012), 251–263.
73. [73] Flaherty, K.T., Infante, J.R., Daud, A., Gonzalez, R., Kefford, R.F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., Kudchadkar, R., Burris, H.A. 3rd, Falchook, G., Algazi, A., Lewis, K., Long, G.V., Puzanov, I., Lebowitz, P., Singh, A., Little, S., Sun, P., Allred, A., Ouellet, D., Kim, K.B., Patel, K., Weber, J., Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367 (2012), 1694–1703.
74. [74] Dan, H.C., Sun, M., Kaneko, S., Feldman, R.I., Nicosia, S.V., Wang, H.G., Tsang, B.K., Cheng, J.Q., Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J. Biol. Chem. 279 (2004), 5405–5412.
75. [75] Szabo, C., Coletta, C., Chao, C., Módis, K., Szczesny, B., Papapetropoulos, A., Hellmich, M.R., Tumor-derived hydrogen sulfide, produced by cystathionine-β-synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 12474––12479.
76. [76] Hellmich, M.R., Coletta, C., Chao, C., Szabo, C., The therapeutic potential of cystathionine β-synthase/hydrogen sulfide inhibition in cancer. Antioxid. Redox Signal. 22 (2015), 424–448, 10.1089/ars.2014.5933.
77. [77] Módis, K., Coletta, C., Asimakopoulou, A., Szczesny, B., Chao, C., Papapetropoulos, A., Hellmich, M.R., Szabo, C., Effect of S-adenosyl-L-methionine (SAM), an allosteric activator of cystathionine β-synthase (CBS) on colorectal cancer cell proliferation and bioenergetics in vitro. Nitric Oxide 41 (2014), 146–156, 10.1016/j.niox.2014.03.001.
78. [78] Szabo, C., Hellmich, M.R., Endogenously produced hydrogen sulfide supports tumor cell growth and proliferation. ABBV Cell Cycle 12 (2013), 2915–2916, 10.4161/cc.26064.
79. [79] Papapetropoulos, Pyriochou, A., Altaany, Z., Yang, G., Marazioti, A., Zhou, Z., Jeschke, M.G., Branski, L.K., Herndon, D.N., Wang, R., Szabó, C., Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 21972–21977.
80. [80] Szabo, C., Gasotransmitters in cancer: from pathophysiology to experimental therapy. Nat. Rev. Drug Discov. 15 (2015), 185–203.